David R. Horn

David R. Horn is the Chief Financial Officer for Seer. Prior to joining Seer, Mr. Horn worked at Morgan Stanley for over 20 years, where he served as a Managing Director in the firm’s Global Healthcare Group within the Investment Banking Department. Mr. Horn was responsible for Morgan Stanley’s global Life Science Tools and Diagnostics practice and oversaw the Western Region Healthcare practice. In addition, Mr. Horn previously spent time working in the medical device and life science sectors where he served as Vice President of Business Development at RITA Medical Systems and, prior to that, in the same role at Chemdex Corporation. Mr. Horn holds a Bachelor of Arts from Princeton University and an MBA from the Stanford University Graduate School of Business.

Omead Ostadan

Omead Ostadan is a member of our Board of Directors and effective on June 29, 2020, he will also join our Executive team as President and Chief Operating Officer. He is currently Chief Product and Marketing Officer and a member of Illumina’s executive management team. He joined Illumina in 2007 as Vice President of Marketing and built the company’s marketing organization during a period of tremendous growth and diversification. In 2011 Mr. Ostadan was Senior Vice President of Product Development and in 2015 his role expanded to include the company’s Global Operations and Quality functions. Prior to joining Illumina, Mr. Ostadan was Vice President of Marketing at Solexa from 2005-2007. Before Solexa, Mr. Ostadan held a variety of marketing roles at Applied Biosystems over a nearly 10-year span, where he managed the company’s high throughput sequencing platforms. Mr. Ostadan holds a BS in Biochemistry from the University of California at Davis and an MBA from The Wharton School at the University of Pennsylvania.

Mostafa Ronaghi

Dr. Ronaghi is the Co-Chairman of the Scientific Advisory Board & Chair of the Technology Committee for Seer.  He is the Chief Technology Officer and SVP at Illumina, where he leads internal research and the Illumina accelerator program.  Before joining Illumina, he founded four life sciences companies – Avantome (acquired by Illumina in 2008); Next Bio (acquired by Illumina in 2013); ParAllele Bioscience (acquired by Affymetrix in 2005); and Pyrosequencing AB (renamed as Biotage in 2003). Dr. Ronaghi was a principal investigator at the Stanford Genome Technology Center at Stanford University from 2002 to 2008, where his research focused on the development of novel molecular diagnostic tools and applications.  He is the inventor of more than 30 patents and the author of more than 70 publications.  Dr. Ronaghi received his B.Sc. in biochemistry from Kalmar University and his Ph.D. in biotechnology from the Royal Institute of Technology in Sweden.

PHILIP MA

Philip Ma is the Chief Business Officer for Seer. Previously, he was Vice-President for Digital Health Technologies and Data Sciences at Biogen, a group that he established in 2015 to discover insights and create value for Biogen and its patients.  Prior to joining Biogen, Philip was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice for the Firm.  Active in community affairs, Philip also serves on the Board of Committee of 100, a group of Chinese-American business and community leaders focused on U.S. China relations and the Asian-American experience. Before McKinsey, Philip was a macromolecular crystallographer in the lab of Dr. Carl O. Pabo at Massachusetts Institute of Technology, where he received his Ph.D. in Biology.  Philip also has degrees in Biochemistry (A.B. from Harvard College) and in Economics (MPhil from Oxford University, where he was a Rhodes Scholar).

Martin Goldberg

Marty currently holds the position of VP, Product Development where he is leading the development of Seer’s Proteograph product, comprised of reagents, consumables, nanoparticles and liquid handling instrument. Previous to Seer he held the position of Sr. VP, Operations at Talis Biomedical Corporation, where he initiated the company’s operational infrastructure. Prior to that, as Sr. VP Research & Development, he oversaw evolution of the company’s technology platform and development of the companies intended 510K CLIA-waived product directed at infectious-disease testing for the point-of-care market. Previously he was the Chief Operating Office at Gen9, a synthetic biology startup, where he oversaw the implementation and commercialization of the company’s first BioFab™ manufacturing facility for the high throughput production of synthetic DNA constructs. Prior to that he worked at Affymetrix in roles of increasing responsibility from establishing and overseeing the company’s first wafer scale manufacturing facility to Sr. VP R&D where he had responsibility for the commercialization of numerous GeneChip® products ranging from new gene expression, genotyping or cytogenetic detection arrays to the launch of the GeneTitan® and GeneAtlas® platforms. Marty holds a PhD in Chemistry from the University of California at San Diego with a focus on physical organometallic chemistry.

Asim Siddiqui

Asim Siddiqui is Vice President of Software and Applications and brings over 20 years of experience in bioinformatics and software engineering to Seer. Prior to Seer, he was Chief Technology Officer at NuMedii responsible for the company’s AI drug discovery platform. Prior to that, he served as Vice President of Product Development at Natera where he built drove Natera’s NIPT diagnostic cloud strategy and critical initiatives. Prior to Natera, Asim led bioinformatics methods and software for next generation sequencing including as Director of Bioinformatics at Life Technologies, where he was awarded the Life Technology Inventor Award. Asim has authored over 30 peer-reviewed publications include articles in Science and Nature. He holds a doctorate in Bioinformatics from Oxford University, and a degree in Physics from Cambridge University.

MARK MCCLELLAN

Dr. McClellan is the Director and Robert J. Margolis MD, Professor of Business, Medicine and Health Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University. Previously, he served as a Senior Fellow in Economic Studies at the Brookings Institution. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services and former commissioner of U.S. Food and Drug Administration (FDA). He previously served as a member of the President’s Council of Economic Advisers, senior director for health care policy at the White House, and Deputy Assistant Secretary for Economic Policy at the Department of the Treasury. Dr. McClellan holds multiple additional roles including, among others: founding chair and current board member, Reagan-Udall Foundation for the FDA; member, National Academy of Medicine; co-chair, guiding committee of the Health Care Payment Learning and Action Network; research associate,  National Bureau of Economic Research; and Senior Faculty Advisor, University of Texas Dell Medical School. Dr. McClellan is also an independent director on the boards of Johnson & Johnson, Cigna and Alignment Healthcare.

ROBERT LANGER

Dr. Langer is the Chair of Seer’s Scientific Advisory Board.  He is an Institute Professor at the Massachusetts Institute of Technology.  Dr. Langer’s scientific work, particularly in drug delivery systems and tissue engineering, has been cited over 275,000 times with an H-Index of 262, and his inventions include over 1300 issued or pending patents.  He is the youngest person ever elected to all three U.S. National Academies (Science, Engineering, and Medicine).  He is one of 4 living individuals to have won both the U.S. National Medal of Science (2006) and the U.S. National Medal of Technology and Innovation (2011); and he has won over 220 other major awards.  He served as a member of the U.S. FDA’s Science Board from 1995 — 2002 and as its Chairman from 1999-2002. Dr. Langer has co-founded over 26 companies, including Moderna, Momenta, and Transform.   Dr. Langer has a bachelor’s degree in chemical engineering from Cornell University and an Sc.D. in chemical engineering from MIT.

John Schembri

John Schembri is Vice President of Finance for Seer and oversees the company’s finances.  John has more than twenty years of experience leading finance at successful, growing biotechnology companies.  He was previously the VP, Finance at Global Blood Therapeutics, where he was responsible for all financial matters, most notably their $120 million initial public offering in 2015.  Prior to that he was CFO of BiPar Sciences, which was acquired by Sanofi-Aventis for $500 million in 2009.  John is a Certified Equity Professional (CEP), holds a Bachelor of Science in accounting from the California Polytechnic State University, San Luis Obispo, California, and is a certified public accountant (CPA, inactive) after working at Deloitte in San Francisco.

BRADLEY HYMAN

Dr. Hyman is John B. Penny Professor of Neurology at Harvard Medical School, and Director of the Massachusetts Alzheimer Disease Research Center at Massachusetts General Hospital, with the goal of understanding the neuropathophysiological and genetic factors that underlie dementia. His own research focuses on understanding the anatomical and molecular basis of dementia in Alzheimer’s Disease and dementia with Lewy bodies. Dr. Hyman also has a clinical practice at Memory and Disorder unit at Massachusetts General Hospital devoted towards the care of patients with dementia. He was awarded the Potamkin Prize in 2006, together with Karen Duff and Karen Ashe, for research achievements in Alzheimer’s Disease. Dr. Hyman received his B.A. from Northwestern University, and his M.D. and Ph.D. degrees from the University of Iowa.

WOLFGANG PARAK

Dr. Parak is Professor of Physics and Chemistry at the University of Hamburg, Germany, and is a Group Leader of the Center of Hybrid Nanostructures at the University.  He was previously Professor of Experimental Physics at the Phillips University of Marburg, Germany and head of the Biofunctional Nanomaterials Unit at CIC biomaGUNE, San Sebastian, Spain.  His research has focused on the interaction of nanoparticles with biological systems, through using the tools of chemistry, physics, and biology to gain fundamental insight into the complexities of the bio-nano interface.  He is the author of over 250 peer-reviewed articles, and an Associate Editor of the journal ACS Nano.  Dr. Parak received his Ph.D. from the Ludwig Maximilians University in Munich, Germany, and also did post-doctoral research at the University of California, Berkeley.

STEVE CARR

Dr. Carr is senior director of proteomics at the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology, chemistry, and medicine. His research has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer and cardiovascular and infectious diseases, as well as pharmacodynamics markers of drug response. Prior to returning to academia in 2004, Dr. Carr held scientific leadership positions at GlaxoSmithKline where he was the director of computational and structural sciences and at Millennium Pharmaceuticals where he was senior director of protein science and technology. He has more than 280 publications, and he is deputy editor of Molecular and Cellular Proteomics, the leading journal in the field of proteomics. Dr. Carr received his B.S. from Union College and Ph.D. from MIT.

Luis A. Diaz, Jr.

Luis Diaz is Head of the Division of Solid Tumor Oncology in Memorial Sloan Kettering’s Department of Medicine.  His research focuses on applied cancer genetics, exploring how cancer genetics can be used to screen for, detect, diagnose, and monitor cancer by looking at DNA in tumor tissue and liquid biopsy.  His work has led to the development of molecular tests for early-stage ovarian cancer and endometrial cancer, which are currently in clinical trials.

Before joining MSKCC, Luis was associate professor of oncology at the Johns Hopkins University School of Medicine. As an entrepreneur, Luis founded Personal Genome Diagnostics in 2010, where he serves on the Board.  Luis received both his undergraduate and medical degrees from the University of Michigan, and he completed post-doctoral training at the Johns Hopkins University.

Lyndal Hesterberg

Lyndal Hesterberg is the Distinguished Fellow at Seer, where he focuses on product development strategy and overall science strategy for the company. Lyndal has over 35 years of biotechnology experience, and is the Principal of HCS Consulting, a company that he formed to provide strategic and operational advice in product development to diagnostic and life sciences companies. Previously, Lyndal was Chief Technology Officer at Crescendo Bioscience, and before that, President and CEO of Barofold, a protein therapeutics company. Earlier in his career, Lyndal was a senior scientific leader at Somalogic, Thermo-Biostar, Amgen, and Syngene. Lyndal received his Ph.D. in Biochemistry from St. Louis University School of Medicine, and his BS in Biochemistry from University of Illinois.

John Blume

John Blume is Vice President, Research and brings almost 30 years’ experience in proteomics, genomics, data analysis, and pre-clinical drug discovery. He was most recently CSO and Scientific Fellow at Drawbridge Health which focused on technologies for blood sampling. Prior to that, John was CSO at Applied Proteomics, a biotechnology company that developed a mass spectrometry-based proteomics platform and launched a CLIA-based colorectal cancer test. As SVP, Product Development at Affymetrix, his portfolio included applications for gene expression analysis, genome wide- and targeted-genotyping, copy number analysis, and variations in drug metabolism. John was also VP, Genomics at Metabolex, a biotechnology company that identified targets for diabetes drug discovery. He started at Novartis where he also focused on diabetes pre-clinical discovery. His post-doctoral fellowship was completed at the Roche Institute of Molecular Biology and his PhD in Biochemistry and Molecular Biology is from the University of Illinois at Urbana-Champaign.

Bill Manning

Bill Manning is Vice President of Product Development at Seer. Prior to Seer, Bill was VP of Lab Operations at Crescendo Bioscience where he led the development and commercialization of Vectra DA, the most successful multi-protein, algorithm-based diagnostic test in the U.S. with more than 1,000,000 tests since launch in 2010.   Before Crescendo, Bill worked in biomarker discovery at Genentech and Sugen where he was responsible for implementing biomarker strategies in clinical development. Prior to this, Bill worked in gene therapy at Chiron Corporation. Bill received his BS in Genetics from Purdue University and his PhD in Molecular Virology from Stanford University.  He has over 20 years’ experience in the biotech industry and has authored more than 28 scientific publications.

Lyssa Friedman

Lyssa Friedman is the Head of Clinical Operations at Seer.  She has over 20 years of experience overseeing clinical research across multiple clinical indications, the last ten years of which have been in the diagnostic space. Lyssa was most recently VP of Clinical Operations at OncoCyte, where she oversaw the development of their oncology clinical programs. Previously, she was VP of Clinical Operations at Veracyte, where she advanced the development of their endocrine and pulmonary products. She has co-authored multiple scientific and clinical abstracts and manuscripts.

Greg Troiano

Greg Troiano is Vice President of Technology and Chief Engineer at Seer. Prior to Seer, Greg was VP of Nanomedicine Development and Manufacturing within Pfizer’s Pharmaceutical Sciences group where he led the development and manufacturing of novel nanoparticle drug products. Over his 20+ year career in the drug delivery field, Greg had various roles leading the pharmaceutical development of complex formulations, including numerous nano- and microparticle based systems. He has led groups for Formulation Development, Process Development, Analytical Development, Supply Chain Management, Manufacturing and Facilities at companies including BIND Therapeutics, Alkermes, and Guilford Pharmaceuticals. Among the products he helped commercialize are Gliadel® Wafer, Nutropin Depot®, Risperdal Consta®, Vivitrol®, and Bydureon®. Greg received his MSE and BS in Biomedical Engineering from The Johns Hopkins University. He has more than 20 process and equipment patents/applications and over a dozen scientific publications in drug delivery.

RALPH WEISSLEDER

Dr. Weissleder is Thrall Professor of Radiology and Professor of Systems Biology at Harvard Medical School, where he is Director of the Center for Systems Biology at Massachusetts General Hospital.  His research focuses on advanced nanomaterials and novel molecular imaging systems, including for early disease detection.  He is the inventor of 27 patents and is the author of over 800 publications (cited over 100,000 times with an H-Index of 166).  Dr. Weissleder is a member of the U.S. National Academy of Medicine, and the German National Academy of Sciences.  He has received numerous awards for his research work, including the J. Taylor International Prize in Medicine, the Millennium Pharmaceuticals Innovator Award, and the Society for Molecular Imaging Lifetime Achievement Award.  As an entrepreneur, he has founded T2 Biosystems, Lumicell, and VisEn Medical (acquired by Perkin Elmer).  Dr. Weissleder received both his M.D. and Ph.D. degrees from the University of Heidelberg.

Dr. Cantor is Professor Emeritus of Biomedical Engineering at Boston University.  He is also the former Chief Scientific Officer of Sequenom, Inc., a San Diego genetics testing company, and now part of Lab Corp. His research has focused on identifying biological problems that are resistant to conventional analytical approaches and then developing new methodologies or techniques for solving these problems.  His laboratory has developed methods for separating large DNA molecules, for studying structural relationships in complex assemblies of proteins and nucleic acids, and for sensitive detection of proteins and nucleic acids in a variety of settings.  He is a member of the U.S. National Academy of Science.  Dr. Cantor has published more than 400 peer reviewed articles, been granted 54 patents, and co-authored a three-volume textbook on Biophysical Chemistry.  He received his A.B. in Chemistry from Columbia University, and his Ph.D. in Biophysical Chemistry from University of California, Berkeley.

Erwin Böttinger

Dr. Böttinger is the inaugural Professor of the Digital Engineering Faculty of Hasso Plattner Institute (HPI) and University of Pottsdam. In his role, he is creating a new academic department in the areas of digital health and healthcare data analyses.  Prior to joining HPI, he was the Chief Executive Officer of the Berlin Institute of Health from 2015 to 2017.  Dr. Böttinger maintains his faculty position as Professor of Medicine for Pharmacology and Systems Therapeutics in the Icahn School of Medicine at Mt. Sinai Hospital, which he joined in 2003.  While at Mt. Sinai, he founded the Charles Bronfman Institute for Personalized Medicine.  Before joining Mt. Sinai, he was on the faculty of Medicine and Molecular Genetics at the Albert Einstein College of Medicine. Dr. Böttinger received his M.D. degree from the University of Erlangen-Nuremberg, and he is also a Board-certified nephrologist where he trained at the Massachusetts General Hospital.

Vivek F. Farias

Dr. Farias is the Chair of the Data Committee of Seer’s Scientific Advisory Board.  He is the Patrick J. McGovern (1959) Professor at the MIT Sloan School, affiliated with the Operations Management and Operations Research Center at MIT. His research focuses on optimization and inference from large-scale stochastic systems (ranging from supply chains to protein networks).  He serves on the editorial boards of the journals Operations Research, Management Science and the Informs Journal on Optimization.  He is also Chief Technology Officer of Celect, a company focused on advanced analytics solutions for supply chains.  Dr. Farias received his B.S. in Computer Engineering from the University of Arizona, and his Ph.D. in Electrical Engineering from Stanford University.

Philip Kantoff

Dr. Kantoff is the Chair of the Clinical Committee of Seer’s Scientific Advisory Board.  He is the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC), where he oversees a department of over 400 physicians and physician scientists.  Before joining MSKCC, he was the Jerome and Nancy Kohlberg Chair at Harvard Medical School and served as the Director of the Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute.  Dr. Kantoff’s research focuses on developing improved treatments for patients with genitourinary cancers, including understanding the molecular basis of prostate cancer.  He serves as Chairman of Prostate Cancer Foundation’s Global Research Council. Dr. Kantoff received his undergraduate and medical degrees from Brown University.

Terry McGuire

Terry McGuire is Founding Partner of Polaris Partners.  As a venture capitalist, he has invested in more than 50 companies, and has also co-founded three companies: Inspire Pharmaceuticals (public and sold to Merck), AIR (sold to Alkemes) and MicroCHIPS (private). Companies that Terry has supported have raised over $6 billion in equity and corporate capital.  In 2013, Terry was listed as one of Forbes’ Top Life Sciences Investors, and in 2011, he was listed in Forbes’ Midas 100 List of Top Tech Investors.  He currently chairs the Board of the Thayer School for Engineering, Dartmouth College, and serves on the Boards of the David Koch Institute for Integrative Cancer Research, the Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS), and the Healthcare Initiative Advisory Board (HBS).  Terry has a BS in physics and economics from Hobart College, an MS in engineering from The Thayer School at Dartmouth College, and an MBA from Harvard Business School.

David Singer

David Singer is Managing Partner of Maverick Capital Ventures, part of Maverick Capital Ltd., an investment fund with almost $11 billion under management. Prior to joining Maverick in 2004, David was a founder and executive for three health care companies – Affymetrix, where he served as President and Chief Executive; Corcept Therapeutics, where he served as its Chief Executive Officer; and GeneSoft Pharmaceuticals, where he served as Chairman.  In addition to GeneSoft, David has also served on the Boards of Pacific Biosciences, Affymetrix, Corcept Therapeutics, and Oscient Pharmaceuticals.  He currently serves on the Board of several private healthcare companies.  David served as a health commissioner of San Francisco and a member of the San Francisco General Hospital Joint Conference Committee.  He has a B.A. degree in history from Yale University and an M.B.A. from Stanford University.

Robert Langer

Dr. Langer is an Institute Professor at the Massachusetts Institute of Technology.  Dr. Langer’s scientific work, particularly in drug delivery systems and tissue engineering, has been cited over 275,000 times with an H-Index of 262, and his inventions include over 1300 issued or pending patents.  He is the youngest person ever elected to all three U.S. National Academies (Science, Engineering, and Medicine).  He is one of 4 living individuals to have won both the U.S. National Medal of Science (2006) and the U.S. National Medal of Technology and Innovation (2011); and he has won over 220 other major awards.  He served as a member of the U.S. FDA’s Science Board from 1995 — 2002 and as its Chairman from 1999-2002. Dr. Langer has co-founded over 26 companies, including Moderna, Momenta, and Transform.   Dr. Langer has a bachelor’s degree in chemical engineering from Cornell University and an Sc.D. in chemical engineering from MIT.

David L. Hallal

David Hallal is Chairman of the Board of Directors at the biotechnology companies iTeos Therapeutics and Scholar Rock.  Prior to his roles at iTeos and Scholar Rock, David was Chief Executive Officer of Alexion Pharmaceuticals, which he first joined in 2006.  In addition to his CEO role, David also served as Board member, Chief Operating Officer, Chief Commercial Officer and Head of Commercial Operations. Before joining Alexion, David served as Vice President of Sales for OSI Eyetech from 2004 to 2006.  He served as Head of Sales at Biogen from 2002 to 2004, and before that, he was at a variety of leadership roles at Amgen from 1992 to 2002. David began his pharmaceutical career at The Upjohn Company, where he was a sales representative from 1998 to 1992. He has a B.A. in psychology from the University of New Hampshire.

Job description: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.